A Multidimensional Analytical Comparison of Remicade and the Biosimilar Remsima
- 17 April 2017
- journal article
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 89 (9), 4838-4846
- https://doi.org/10.1021/acs.analchem.6b04436
Abstract
In April 2016, the Food and Drug Administration approved the first biosimilar monoclonal antibody (mAb), Inflectra/Remsima (Celltrion), based off the original product Remicade (infliximab, Janssen). Biosimilars promise significant cost savings for patients, but the unavoidable differences between innovator and copycat biologics raise questions regarding product interchangeability. In this study, Remicade and Remsima were examined by native mass spectrometry, ion mobility, and quantitative peptide mapping. The levels of oxidation, deamidation, and mutation of individual amino acids were remarkably similar. We found different levels of C-terminal truncation, soluble protein aggregates, and glycation that all likely have a limited clinical impact. Importantly, we identified more than 25 glycoforms for each product and observed glycoform population differences, with afucosylated glycans accounting for 19.7% of Remicade and 13.2% of Remsima glycoforms, which translated into a 2-fold reduction in the level of FcγIIIa receptor binding for Remsima. While this difference was acknowledged in Remsima regulatory filings, our glycoform analysis and receptor binding results appear to be somewhat different from the published values, likely because of methodological differences between laboratories and improved glycoform identification by our laboratory using a peptide map-based method. Our mass spectrometry-based analysis provides rapid and robust analytical information vital for biosimilar development. We have demonstrated the utility of our multiple-attribute monitoring workflow using the model mAbs Remicade and Remsima and have provided a template for analysis of future mAb biosimilars.Keywords
Funding Information
- Ministry of Health and Welfare (U01 FD004275)
- American Foundation for Pharmaceutical Education
- U.S. Department of Health and Human Services (R01 GM090080, R44GM100634)
- National Science Foundation (1253384)
This publication has 33 references indexed in Scilit:
- The Tortoise and the Hare: Evolving Regulatory Landscapes for BiosimilarsTrends in Biotechnology, 2016
- Use of Biosimilars in Paediatric Inflammatory Bowel DiseaseJournal of Pediatric Gastroenterology and Nutrition, 2015
- Biosimilars in rheumatology: current perspectives and lessons learntNature Reviews Rheumatology, 2015
- Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn’s DiseaseClinical Pharmacokinetics, 2014
- Biopharmaceutical benchmarks 2014Nature Biotechnology, 2014
- Physicochemical characterization of Remsima®mAbs, 2014
- ECCO position statement: The use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD)Journal of Crohn's and Colitis, 2013
- Developing the Nation's Biosimilars ProgramNew England Journal of Medicine, 2011
- Biosimilar therapeutics--what do we need to consider?NDT Plus, 2009
- Biosimilars: the impact of their heterogeneity on regulatory approvalNature Reviews Drug Discovery, 2007